4//SEC Filing
Shearman Mark S 4
Accession 0001415889-22-001224
CIK 0001650664other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 4:21 PM ET
Size
7.2 KB
Accession
0001415889-22-001224
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
2022-02-10+31,709→ 73,494 total - Award
Stock Option (right to buy)
2022-02-10+93,398→ 93,398 totalExercise: $17.29Exp: 2032-02-09→ Common Stock (93,398 underlying)
Footnotes (2)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026.
- [F2]This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026.
Documents
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001643799
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 4:21 PM ET
- Size
- 7.2 KB